← All trials
NCT05161468
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- May 31, 2024
- First posted
- Dec 17, 2021
- Last posted
- Dec 17, 2021
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- United States ArmyLead sponsor
- United States ArmyCollaborator
- Uniformed Services University of the Health SciencesOverall official - principal investigator
- Uniformed Services University of the Health SciencesCollaborator
- The Geneva FoundationCollaborator
- United States ArmyReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.